One of the more noteworthy developments in recent days has been the move in biotech. The iShares Nasdaq Biotechnology ETF (IBB) now up about 12% from its November lows to trade at 112, near two-year nigh. Not only is that IBB overbought following recent advance, the ETF also drawing the attention of bears. Now ...[read more]
↧